Exelixis (NASDAQ:EXEL – Get Free Report) had its price target raised by research analysts at UBS Group from $30.00 to $34.00 ...

Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company with a market capitalization of $9.4 billion focused on developing and commercializing novel therapies for cancer treatment, stands at a ...

Guggenheim analyst Michael Schmidt maintained a Buy rating on Zentalis Pharmaceuticals (ZNTL – Research Report) yesterday and set a price ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.